Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation : An analysis from the acute leukemia working party of the EBMT

Show full item record



Permalink

http://hdl.handle.net/10138/206991

Citation

Canaani , J , Labopin , M , Socie , G , Nihtinen , A , Huynh , A , Cornelissen , J , Deconinck , E , Gedde-Dahl , T , Forcade , E , Chevallier , P , Bourhis , J H , Blaise , D , Mohty , M & Nagler , A 2017 , ' Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation : An analysis from the acute leukemia working party of the EBMT ' , American Journal of Hematology , vol. 92 , no. 7 , pp. 653-659 . https://doi.org/10.1002/ajh.24737

Title: Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation : An analysis from the acute leukemia working party of the EBMT
Author: Canaani, Jonathan; Labopin, Myriam; Socie, Gerard; Nihtinen, Anne; Huynh, Anne; Cornelissen, Jan; Deconinck, Eric; Gedde-Dahl, Tobias; Forcade, Edouard; Chevallier, Patrice; Bourhis, Jean H.; Blaise, Didier; Mohty, Mohamad; Nagler, Arnon
Contributor: University of Helsinki, Hematologian yksikkö
Date: 2017-07
Language: eng
Number of pages: 7
Belongs to series: American Journal of Hematology
ISSN: 0361-8609
URI: http://hdl.handle.net/10138/206991
Abstract: Up to 20% of acute myeloid leukemia (AML) patients present initially with hyperleukocytosis, placing them at increased risk for early mortality during induction. Yet, it is unknown whether hyperleukocytosis still retains prognostic value for AML patients undergoing hematopoietic stem cell transplantation (HSCT). Furthermore, it is unknown whether hyperleukocytosis holds prognostic significance when modern molecular markers such as FLT3-ITD and NPM1 are accounted for. To determine whether hyperleukocytosis is an independent prognostic factor influencing outcome in transplanted AML patients we performed a retrospective analysis using the registry of the acute leukemia working party of the European Society of Blood and Marrow Transplantation. A cohort of 357 patients with hyperleukocytosis (159 patients with white blood count [WBC] 50 K-100 K, 198 patients with WBC >= 100 K) was compared to 918 patients without hyperleukocytosis. Patients with hyperleukocytosis were younger, had an increased rate of favorable risk cytogenetics, and more likely to be FLT3 and NPM1 mutated. In multivariate analysis, hyperleukocytosis was independently associated with increased relapse incidence (hazard ratio [HR] of 1.55, 95% confidence interval [CI], 1.14-2.12; P = .004), decreased leukemia-free survival (HR of 1.38, 95% CI, 1.07-1.78; P = .013), and inferior overall survival (HR of 1.4, 95% CI, 1.07-1.84; P = .013). Hyperleukocytosis retains a significant prognostic role for AML patients undergoing HSCT.
Subject: ACUTE MYELOGENOUS LEUKEMIA
ACUTE MYELOBLASTIC-LEUKEMIA
EARLY MORTALITY
EUROPEAN LEUKEMIANET
LEUKOCYTE COUNT
LEUKAPHERESIS
AML
REMISSION
LEUKOSTASIS
MANAGEMENT
3122 Cancers
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
Canaani_et_al_2 ... _Journal_of_Hematology.pdf 588.4Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record